Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA ...

Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the only US FDA-approved medication for the treatment of gastroparesis. However, the FDA ...

Many patients with severe gastroparesis unfortunately do not achieve adequate relief from the previously outlined therapies. In such cases, consideration should be given to implantation of a ...

Vanda Pharmaceuticals (VNDA) issued a letter to FDA Commissioner highlighting what the company considers a faulty gastroparesis NDA review.

FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025. Gimoti remains only approved drug shown to reduce hospitalizations, emergency ...

As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients ...

GIMOTI® (metoclopramide) nasal spray remains the sole FDA-approved treatment for diabetic gastroparesis, providing effective symptom relief and substantial cost savings compared to oral ...